Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2023-11-07
Target enrollment:
Participant gender:
Summary
This research protocol will evaluate the feasibility of administering neoadjuvant gemcitabine
and nab-paclitaxel with hypofractionated, image guided, intensity modulated radiotherapy
(HIGRT) in resectable and borderline resectable pancreatic cancer